HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Attenuation of inflammation and cytokine production in rat colitis by a novel selective inhibitor of leukotriene A4 hydrolase.

AbstractBACKGROUND AND PURPOSE:
Leukotriene B(4) (LTB(4)), formed by the sequential actions of the 5-lipoxygenase (5-LO) and leukotriene A(4) hydrolase (LTA(4)H), is a pro-inflammatory mediator implicated in the pathogenesis of inflammatory bowel disease. However, inhibitors of 5-LO have not proved to be consistent in their therapeutic efficacy in colitis. Another approach to inhibiting LTB(4) synthesis is through the use of inhibitors of LTA(4)H, such as the novel, potent and selective compound, JNJ 26993135.
EXPERIMENTAL APPROACH:
The effect of oral administration of JNJ 26993135 has been evaluated in a rat model of colitis provoked by colonic instillation of trinitrobenzenesulphonic acid (TNBS). The extent and severity of the macroscopic inflammatory response, the colonic levels of myeloperoxidase (MPO) and LTB(4) and of the pro-inflammatory cytokines, tumour necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) were measured.
KEY RESULTS:
Oral administration of JNJ 26993135 (5, 15 and 30 mg kg(-1), twice a day) dose-dependently reduced both the extent and intensity of the colonic inflammatory damage observed 3 days after TNBS challenge. JNJ 26993135 also dose-dependently reduced the elevated colonic levels of LTB(4), as well as the inflammatory biomarkers, MPO, IL-6 and TNF-alpha. This dosing regimen was supported by the pharmacokinetic profile of JNJ 26993135, along with the demonstration of the inhibition of ex vivo production of LTB(4) in whole blood following oral administration.
CONCLUSIONS AND IMPLICATIONS:
These results with JNJ 26993135 in the rat TNBS model support the role of LTB(4) in colitis and the potential value of targeting LTA(4)H for the treatment of inflammatory bowel diseases.
AuthorsB J R Whittle, C Varga, A Berko, K Horvath, A Posa, J P Riley, K A Lundeen, A M Fourie, P J Dunford
JournalBritish journal of pharmacology (Br J Pharmacol) Vol. 153 Issue 5 Pg. 983-91 (Mar 2008) ISSN: 0007-1188 [Print] England
PMID18157165 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Benzothiazoles
  • Enzyme Inhibitors
  • Interleukin-6
  • Piperidines
  • Tumor Necrosis Factor-alpha
  • 1-(4-(benzothiazol-2-yloxy)benzyl)piperidine-4-carboxylic acid
  • Trinitrobenzenesulfonic Acid
  • Peroxidase
  • Epoxide Hydrolases
  • leukotriene A4 hydrolase
Topics
  • Administration, Oral
  • Animals
  • Benzothiazoles (administration & dosage, pharmacokinetics, pharmacology)
  • Colitis (chemically induced, drug therapy, physiopathology)
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Drug Delivery Systems
  • Enzyme Inhibitors (administration & dosage, pharmacokinetics, pharmacology)
  • Epoxide Hydrolases (antagonists & inhibitors)
  • Inflammation (drug therapy, etiology)
  • Interleukin-6 (metabolism)
  • Male
  • Peroxidase (drug effects, metabolism)
  • Piperidines (administration & dosage, pharmacokinetics, pharmacology)
  • Rats
  • Rats, Wistar
  • Severity of Illness Index
  • Trinitrobenzenesulfonic Acid
  • Tumor Necrosis Factor-alpha (drug effects, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: